Literature DB >> 17021137

e19a2 BCR-ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases.

B C Mondal1, S Majumdar, U B Dasgupta, U Chaudhuri, P Chakrabarti, S Bhattacharyya.   

Abstract

This report describes two patients with chronic myeloid leukaemia (CML): one of them developed accelerated phase CML and died 8 years after diagnosis and the other is at the chronic phase. Sequence analysis of reverse transcription-polymerase chain reaction products showed the presence of BCR-ABL fusion transcript e19a2. This finding suggests that CML carrying mu-BCR breakpoint may exhibit a clinical course similar to typical CML.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17021137      PMCID： PMC1861751          DOI： 10.1136/jcp.2005.029595

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


  9 in total

Review 1.  p230 does not always predict a mild clinical course in myeloid malignancies: e19a2 bcr/abl fusion transcript with additional chromosome abnormalities in a patient with acute monoblastic leukemia (M5a).

Authors:  P Bernasconi; S Calatroni; M Boni; P M Cavigliano; G Pagnucco; C Bernasconi
Journal:  Haematologica       Date:  2001-03       Impact factor: 9.941

2.  Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases.

Authors:  Joaquín Martínez-López; Rosa Ayala; Queta Albizua
Journal:  Haematologica       Date:  2002-08       Impact factor: 9.941

3.  Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)

Authors:  F Pane; F Frigeri; M Sindona; L Luciano; F Ferrara; R Cimino; G Meloni; G Saglio; F Salvatore; B Rotoli
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

4.  A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease?

Authors:  H Mittre; P Leymarie; M Macro; M Leporrier
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

5.  Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.

Authors:  R C Quackenbush; G W Reuther; J P Miller; K D Courtney; W S Pear; A M Pendergast
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

6.  Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis.

Authors:  Koiti Inokuchi; Kazuo Dan; Miyuki Takatori; Hidemasa Takahuji; Naoya Uchida; Mitsuharu Inami; Koichi Miyake; Hiroaki Honda; Hisamaru Hirai; Takashi Shimada
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

7.  New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia.

Authors:  G Saglio; A Guerrasio; C Rosso; A Zaccaria; A Tassinari; A Serra; G Rege-Cambrin; U Mazza; F Gavosto
Journal:  Blood       Date:  1990-11-01       Impact factor: 22.113

8.  P230 BCR/ABL protein may be associated with an acute leukaemia phenotype.

Authors:  C Haskovec; C Ponzetto; J Polák; D Maritano; Z Zemanová; A Serra; K Michalová; H Klamová; J Cermák; G Saglio
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

9.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307
  9 in total
  8 in total

Review 1.  Targeted therapy of chronic myeloid leukemia.

Authors:  Con Sullivan; Cong Peng; Yaoyu Chen; Dongguang Li; Shaoguang Li
Journal:  Biochem Pharmacol       Date:  2010-05-12       Impact factor: 5.858

2.  Chronic Myeloid Leukemia with e19a2 BCR-ABL1 Transcripts and Marked Thrombocytosis: The Role of Molecular Monitoring.

Authors:  Stephen E Langabeer; Sarah L McCarron; Johanna Kelly; Janusz Krawczyk; Suzanne McPherson; Kanthi Perera; Philip T Murphy
Journal:  Case Rep Hematol       Date:  2012-07-02

3.  Early Complete Molecular Response to First-Line Nilotinib in Two Patients with Chronic Myeloid Leukemia Carrying the p230 Transcript.

Authors:  Marianna Greco; Giovanni Caocci; Giorgio La Nasa
Journal:  Case Rep Hematol       Date:  2013-07-11

4.  Identification of potential drug targets implicated in Parkinson's disease from human genome: insights of using fused domains in hypothetical proteins as probes.

Authors:  N Rathankar; K A Nirmala; Varun Khanduja; H G Nagendra
Journal:  ISRN Neurol       Date:  2011-09-04

5.  Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients.

Authors:  S Rajashree Nandagopalan; Nivedita Kuila; Sutapa Biswas; Naresh Chandra Pattnayak; Gyanashyam Biswas; Soumen Chakraborty
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

6.  P190 BCR-ABL1 in a Patient with Philadelphia Chromosome Positive T-Cell Acute Lymphoblastic Leukemia: A Rare Case Report and Review of Literature.

Authors:  Samah Kohla; Sarah El Kourashy; Zafar Nawaz; Reda Youssef; Ahmad Al-Sabbagh; Feryal A Ibrahim
Journal:  Case Rep Oncol       Date:  2021-07-01

7.  Rapid Evolution to Blast Crisis Associated with a Q252H ABL1 Kinase Domain Mutation in e19a2 BCR-ABL1 Chronic Myeloid Leukaemia.

Authors:  Sarah L McCarron; Karena Maher; Johanna Kelly; Mary F Ryan; Stephen E Langabeer
Journal:  Case Rep Hematol       Date:  2013-09-16

Review 8.  Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia.

Authors:  Matteo Molica; Elisabetta Abruzzese; Massimo Breccia
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-09-01       Impact factor: 2.576
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.